GnRH agonist for final oocyte maturation in GnRH antagonist co-treated IVF/ICSI treatment cycles: Systematic review and meta-analysis

Journal of Advanced Research

Volumn 6, Issue 3, 2015, Pages 341-349

  Youssef, M A F ^a   Abdelmoty, Hatem I ^a   Ahmed, Mohamed A S ^b   Elmohamady, Maged ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b BENI SUEF UNIVERSITY   (Egypt)

Author keywords

GnRH agonist; GnRH antagonist; HCG; OHSS

Indexed keywords

EID: 84937630760     PISSN: 20901232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jare.2015.01.005     Document Type: Review

References (26)

1. Check J., Nazari A., Barnea E., Weiss W., Vetter B. The efficacy of short-term gonadotrophin-releasing hormone agonists versus human chorionic gonadotrophin to enable oocyte release in gonadotrophin stimulated cycles. Hum Reprod 1993, 8:568-571.
2. Youssef M.A., Van der Veen F., Al-Inany H.G., Griesinger G., Mochtar M.H., Aboulfoutouh I., Khattab S.M., van Wely M. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles. Cochrane Database Syst Rev 2011, 19(1):CD008046.
3. Pirard C., Donnez J., Loumaye E. GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study. Hum Reprod 2006, 21(7):1894-1900.
4. Engmann L., DiLuigi A., Schmidt D., Nulsen J., Maier D., Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after co-treatment with GnRH antagonist in high-risk patients unde going in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril 2008, 89(1):84-91.
5. Humaidan P., Bredkjær H.E., Westergaard L., Andersen C.Y. 1500IU hCG secures a normal clinical pregnancy outcome in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist. Fertil Steril 2010, 93(3):847-854.
6. Simon C., Cano F., Valbuena D., Remohi J., Pellicer A. Clinical evidence for a detrimental effect on uterine receptivity of high serum estradiol concentrations in high and normal responders. Hum Reprod 1995, 10:2432-2437.
7. Forman R., Fries N., Tastart J., Belaisch J., Hazout A., Frydman R. Evidence of an adverse effect of elevated serum estradiol concentrations on embryo implantation. Fertil Steril 1998, 49:118-122.
8. Simon C., Garcia Velasco J.J., Valbuena D., Peinado J.A., Moreno C., Rehmohi J., et al. Increasing uterine receptivity by decreasing estradiol levels during the preimplantation period in high responders with the use of a follicle-stimulating hormone step-down regimen. Fertil Steril 1998, 70:234-239.
9. Valbuena D., Martin J., de Palbo J.L., Remohi J., Pellicer A., Simon C. Increasing levels of estradiol are deleterious to embryonic implantation because they directly affect the embryo. Fertil Steril 2001, 76:962-968.
10. Tavaniotou A., Albano C., Smitz J., Devroey P. Impact of ovarian stimulation on corpus luteum function and embryonic implantation. J Reprod Immunol 2002, 55:123-130.
11. Cerrillo M, Pacheco A, Rodríguez S, Mayoral M, Ruiz M, García Velasco JA. Differential regulation of VEGF, Cadherin, and Angiopietin 2 by trigger oocyte maturation with GnRHa vs hCG in donors: try to explain the lower OHSS incidence. In: Abstracts of the 25th annual meeting of the ESHRE, Amsterdam, June 28-1 July; 2009, vol. 24, 1, p. i60.
12. Delvigne A., Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update 2002, 8(6):559-577.
13. Acevedo B., Jose Gomez-Palomares L., Ricciarelli E., Hernández E.R. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates. Fertil Steril 2006, 86(6):1682-1687.
14. Babayof R., Margalioth J.E., Huleihel M., Amash A., Zylber-Haran E., Gal M., et al. Serum inhibin A VEGF and TNFa levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Hum Reprod 2006, 21(5):1260-1265.
15. Beckers N.G., Macklon N.S., Eijkemans M.J., Ludwig M., Felberbaum R.E., Diedrich K., et al. Non supplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. J Clin Endocrinol Metab 2003, 88(9):4186-4192.
16. Fauser B.C., De Jong D., Olivennes F., Warmsby H., Tay C.J., Itskovitz-Eldor J., Van Hooren H.G. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab 2002, 87(2):709-715.
17. Galindo A., Bodri D., Guillén J.J., Colodrón M., Vernaeve V., Coll O. Triggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial. Gynecol Endocrinol 2009, 25:60-66.
18. Humaidan P., Bredkjær H.E., Bungum L., Bungum M., Grøndahl M.L., Westergaard L., Andersen C.Y. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod 2005, 20(5):1213-1220.
19. Humaidan P., Bungum M., Andersen C.Y. Rescue of corpus luteum function with periovulatoryHCG supplementation in IVF/ICSIGnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. Reprod Biomed Online 2006, 13(2):173-178.
20. Kolibianakis E.M., Schultze-Mosgau A., Schroer A., Van Steirteghem A., Devroey P., Diedrich K., Griesinger G. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Hum Reprod 2005, 20(10):2887-2892.
21. Papanikolaou E.G., Verpoest W., Fatemi H., Tarlatzis B., Devroey P., Tournaye H. A novel method of luteal supplementation with recombinant luteinizing hormone when a gonadotropin-releasing hormone agonist is used instead of human chorionic gonadotropin for ovulation triggering: a randomized prospective proof of concept study. Fertil Steril 2011, 95(3):1174-1177.
22. Schachter M., Friedler S., Ron-El R., Zimmerman A.L., Strassburger D., Bern O., et al. Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective, randomized study. Fertil Steril 2008, 90(4):1087-1093.
23. Sismanoglu A1, Tekin H.I., Erden H.F., Ciray N.H., Ulug U., Bahceci M. Ovulation triggering with GnRH agonist vs. hCG in the same egg donor population undergoing donor oocyte cycles with GnRH antagonist: a prospective randomized cross-over trial. J Assist Reprod Genet 2009, 26(5):251-256.
24. Melo M1, Busso C.E., Bellver J., Alama P., Garrido N., Meseguer M., Pellicer A., Remohí J. GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessor-blind study. Reprod Biomed Online 2009, 19(4):486-492.
25. Griesinger G., Berndt H., Schultz L., Depenbusch M., Schultze-Mosgau A. Cumulative live birth rates after GnRH-agonist triggering of final oocyte maturation in patients at risk of OHSS: a prospective, clinical cohort study. Eur J Obstet Gynecol Reprod Biol 2010, 149(2):190-194.
26. Griesinger G., von Otte S., Schroer A., Ludwig A.K., Diedrich K., Al-Hasani S., Schultze-Mosgau A. Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: a prospective, observational proof-of-concept study. Hum Reprod 2007, 22(5):1348-1352.